← All stocks

Fulcrum Therapeutics, Inc.

FULC Net selling
CIK 0001680581 #3613 in the set updated 17 Sep 2026
Bought (120 mo)
$51.62M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$66.53M
$0.00 on a plan · $6.09M straight out of an exercise
Sold at will
$60.44M
41 of 69 sales
Net
−$14.91M
−$8.82M against sales at will

By person

22 insiders · 98 transactions
1.0×

Alex C. Sapir holds only 1.0 times base salary in stock. $680.63K of shares against $650.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Alex C. Sapir last reported holding, valued at $3.52, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
$40.00M (8)
$58.38M (3)
−$18.38M
6,053,960
$21.31M
−57.1%
Gould Robert J
Director
$4.94M (29) scheduled
−$4.94M
454,864
$1.60M
−18.4%
Casdin Capital, LLC entity
10% owner
$2.22M (3)
+$2.22M
604,285
$2.13M
6 Dimensions Capital, L.P. entity
10% owner
$1.90M (1)
+$1.90M
559,821
$1.97M
Sanofi
10% owner
$1.50M (1)
+$1.50M
558,035
$1.96M
TANG KEVIN
10% owner
$1.49M (6)
+$1.49M
7,080,945
$24.92M
+6.3%
LEVIN MARK J
Director
$1.30M (1)
+$1.30M
9,924,404
$34.93M
+58.8%
Third Rock Ventures III, L.P. entity
10% owner
$1.30M (1)
+$1.30M
1,962,202
$6.91M
+586.8%
Third Rock Ventures IV, L.P. entity
10% owner
$1.30M (1)
+$1.30M
2,343,154
$8.25M
Stuart Bryan
See Remarks
$1.23M (2) scheduled
−$1.23M
0
$0.00
Moxham Christopher
Chief Scientific Officer
$911.42K (2) scheduled
−$911.42K
31,071
$109.37K
0.0%
Sapir Alex
See Remarks
$492.03K (1)
+$492.03K
193,360
$680.63K
Thomson Peter G.
VP Finance & Accounting
$20.70K (1)
$456.33K (8)
−$435.63K
17,512
$61.64K
−55.5%
Wallace Owen B.
Chief Scientific Officer
$245.44K (6) scheduled
−$245.44K
133,438
$469.70K
+5.0%
Cadavid Diego
SVP Clinical Development
$205.75K (13) scheduled
−$205.75K
65,714
$231.31K
−7.5%
GERAGHTY JAMES A
Director
$91.60K (1)
+$91.60K
90,714
$319.31K
+12.4%
Ezekowitz Alan
Director
$65.61K (1)
−$65.61K
10,927
$38.46K
−62.2%
Tourangeau Greg
Principal Accounting Officer
$62.26K (4)
−$62.26K
14,062
$49.50K
−15.5%
Oltmans Curtis Gale
Chief Legal Officer
$9.80K (1)
$44.60K (1)
−$34.80K
10,252
$36.09K
−18.7%
Morabito Christopher
Chief Medical Officer
$10.08K (1)
+$10.08K
1,100
$3.87K
GSK plc entity
10% owner
1,785,714
$6.29M
Section 32 Fund 2, LP entity
10% owner
464,285
$1.63M

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Insider
Date
Role
Action
Shares
Price
Amount
Gould Robert J
7 Jun 2022
Director
Sold after exercise
71,435
$8.09
$577.89K
Gould Robert J
6 Jun 2022
Director
Sold after exercise
24,382
$8.10
$197.59K
Gould Robert J
3 Jun 2022
Director
Sold after exercise
25,551
$7.95
$203.06K
Gould Robert J
2 Jun 2022
Director
Sold after exercise
16,689
$7.92
$132.16K
Gould Robert J
7 Apr 2022
Director
Sold after exercise
5,631
$24.02
$135.23K
Gould Robert J
5 Apr 2022
Director
Sold after exercise
52,552
$24.26
$1.27M
Gould Robert J
4 Apr 2022
Director
Sold after exercise
7,235
$24.02
$173.75K
Gould Robert J
1 Apr 2022
Director
Sold after exercise
34,464
$24.03
$828.16K
Stuart Bryan
11 Aug 2021
See Remarks
Sold after exercise
28,000
$23.75
$665.00K
Stuart Bryan
10 Aug 2021
See Remarks
Sold after exercise
32,000
$17.50
$560.00K
Moxham Christopher
10 Aug 2021
Chief Scientific Officer
Sold after exercise
31,071
$18.00
$559.28K
Moxham Christopher
10 Aug 2021
Chief Scientific Officer
Sold after exercise
20,714
$17.00
$352.14K
Thomson Peter G.
22 Feb 2021
VP Finance & Accounting
Sold after exercise
5,000
$14.72
$73.58K
Wallace Owen B.
8 Jul 2020
Chief Scientific Officer
Sold after exercise
2,951
$20.00
$59.02K
Wallace Owen B.
30 Jun 2020
Chief Scientific Officer
Sold after exercise
141
$20.00
$2.82K
Cadavid Diego
25 Jun 2020
SVP Clinical Development
Sold after exercise
1,459
$22.00
$32.10K
Cadavid Diego
10 Jun 2020
SVP Clinical Development
Sold after exercise
401
$22.00
$8.82K
Cadavid Diego
5 Jun 2020
SVP Clinical Development
Sold after exercise
451
$20.18
$9.10K
Cadavid Diego
4 Jun 2020
SVP Clinical Development
Sold after exercise
226
$20.05
$4.53K
Cadavid Diego
3 Jun 2020
SVP Clinical Development
Sold after exercise
338
$20.18
$6.82K
Cadavid Diego
2 Jun 2020
SVP Clinical Development
Sold after exercise
45
$20.00
$900.00
Cadavid Diego
29 May 2020
SVP Clinical Development
Sold after exercise
200
$20.04
$4.01K
Wallace Owen B.
28 May 2020
Chief Scientific Officer
Sold after exercise
2,232
$20.00
$44.64K
Cadavid Diego
28 May 2020
SVP Clinical Development
Sold after exercise
600
$20.00
$12.00K
Wallace Owen B.
27 May 2020
Chief Scientific Officer
Sold after exercise
448
$20.00
$8.96K
Wallace Owen B.
26 May 2020
Chief Scientific Officer
Sold after exercise
412
$20.00
$8.24K
Cadavid Diego
12 May 2020
SVP Clinical Development
Sold after exercise
1,860
$18.00
$33.48K
Wallace Owen B.
19 Feb 2020
Chief Scientific Officer
Sold after exercise
6,088
$20.00
$121.76K

What was left out

Form 4 filings counted 183
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 16
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 28
Sales at will 41
Transactions with no price 0
Shares from compensation/vesting 32,104,196
Sales filed before the plan box existed 29
History held since 18 Jul 2019